LANSING, Mich., Dec. 29, 2022 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023.
John Adent, Neogen's President and Chief Executive Officer, will present at 8:15 a.m. Pacific Time.
To access the webcast and presentation materials, please visit the Events & Presentations section of the Neogen Investor Relations website at neogen.com/investor-relations/events-presentations and click on the event webcast link.
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.
CONTACT : | Bill Waelke, Investor Relations |
Last Trade: | US$14.90 |
Daily Change: | -0.19 -1.26 |
Daily Volume: | 1,184,755 |
Market Cap: | US$3.230B |
October 10, 2024 July 30, 2024 June 27, 2024 April 09, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB